Poseida Therapeutics: Harry J. Leonhardt is the new GC
Harry J. Leonhardt has joined Poseida Therapeutics as general counsel and chief compliance officer.
Leonhardt served as senior vice president, general counsel, chief compliance officer and corporate secretary and a member of the executive committee for Halozyme Therapeutics where he provided strategic counsel on a broad range of legal matters for the company and its board of directors.
Prior to Halozyme, Leonhardt served as Senior Vice President, Legal and Compliance & Corporate Secretary and as a member of the executive committee for Amylin Pharmaceuticals, which was acquired by Bristol-Myers Squibb in 2012. Prior to that time, Leonhardt served as General Counsel for a number of San Diego-based biotech companies, and as Chief Litigation Counsel and later as General Counsel for the European Region at Allergan Pharmaceuticals. Prior to that time Mr. Leonhardt was an intellectual property litigator in Los Angeles.